Brady Stock Is up 13% This Past Year, but Here's Why One Fund Cashed Out Completely

Paradiem disclosed in a 13F filing that it sold its entire 166,374-share stake in Brady Corporation (NYSE: BRC) in Q4, an estimated $12.98 million transaction based on the quarter's average closing price; the position had represented ~3.03% of the fund’s AUM. Brady, trading at $80.80 (one‑year +12.58%), reported TTM revenue of $1.54 billion and net income of $196.41 million; in the most recent quarter sales rose 7.5% to $405.3 million, adjusted diluted EPS increased 8% to $1.21, operating cash flow jumped 42.5% to $33.4 million, management raised the low end of full‑year adjusted EPS guidance to $4.90–$5.15, and the company ended the quarter with roughly $67 million of net cash—suggesting the sale is likely portfolio reallocation rather than a signal of deteriorating fundamentals.

Analysis

Market structure: Paradiem’s $12.98M sale of 166,374 BRC shares (~0.35% of outstanding shares; BRC market cap $3.81B) is a fund-level reallocation rather than a liquidation signal for the name — mathematically small but telling about sentiment tilt toward higher-beta capex names (LRCX, CAT, VLO). Immediate selling pressure on BRC should be limited; the more important signal is capital flowing into semicap/industrial cyclicals which can lift supplier multiples over the next 3–9 months if macro data (ISM >50, SEMI book-to-bill >1.0) confirm demand.

Risk assessment: Key downside tail risks for BRC include a sharp industrial recession (manufacturing PMI <48 for two months), a >5% cut to FY adjusted EPS guidance, or supply-chain tariff shocks that compress margins; any of these would materially reduce free cash flow given TTM revenue $1.54B and quarterly OCF $33.4M. Short-term (days-weeks) volatility likely modest; watch next quarter’s OCF and guidance in 30–90 days; long-term (quarters-years) risks center on cyclical exposure and potential margin pressure from raw-material inflation or failed M&A integration.

Trade implications: If you want exposure to the rotation, favor LRCX/CAT over BRC for 3–9 month cyclical upside; if you prefer defensive steady cashflow, BRC is a buy-on-dip candidate given net cash ~$67M and raised EPS guide. Use relative trades: dollar-neutral long LRCX / short BRC over 3–6 months to capture capex vs. identification-equipment divergence; for income, sell 1–3 month covered calls on BRC ~10% OTM to harvest premium while retaining upside.

Contrarian angles: The consensus misses that Paradiem’s move may compress BRC momentum short-term but creates a purposeful buying opportunity — fundamentals (7.5% sales growth, +8% adj EPS) justify accumulation if price falls ~10%. Historical parallels: mid-cap industrials often lag early-cycle cyclicals by 3–6 months then catch up; if ISM and semicap orders strengthen, BRC could re-rate along with broader industrial multiple expansion, so avoid reflexive shorting absent macro deterioration.

Key Decisions for Investors

• Establish a 2–3% portfolio long in BRC (Brady Corp) now or on pullback to $73 (≈10% below $80.80). Add to 4% if next two quarters confirm OCF > $30M and FY adj EPS remains within or above $4.90–$5.15; cut to zero if FY adj EPS guidance is reduced >5% or quarterly OCF falls below $25M.
• Initiate a 2–4% long position in LRCX (Lam Research) to play semiconductor capex rotation for a 3–9 month horizon; target +15–25% upside or a stop-loss at −12%. If SEMI book-to-bill >1.0 for two consecutive months, add another 1–2%.
• Implement a dollar-neutral pair: long LRCX / short BRC (1–2% each) for 3–6 months to capture relative capitalization-weighted rotation; unwind if the long outperforms the short by +8% or if macro PMI falls below 48 for two months.
• If holding BRC for income, sell 1–3 month covered calls ~10% OTM (strike ≈ $89) to generate yield (~target 3–6% premium). Alternatively, buy a 9–12 month BRC protective put spread (e.g., buy 10% ITM put / sell 25% OTM put) if S&P falls >5% in 30 days or BRC breaks below its 200-day MA.